Pradaxa Side Effects Center

Last updated on RxList: 3/29/2022
Pradaxa Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Pradaxa?

Pradaxa (dabigatran) is an anticoagulant that works by blocking the clotting protein thrombin. Pradaxa is used to prevent blood clots from forming because of a certain irregular heart rhythm (atrial fibrillation). Preventing these blood clots helps to reduce the risk of a stroke.

What Are Side Effects of Pradaxa?

Side effects of Pradaxa include:

  • bruising and minor bleeding (such as nosebleeds and bleeding from cuts),
  • nausea,
  • abdominal or stomach pain,
  • stomach upset,
  • indigestion,
  • heartburn,
  • diarrhea,
  • skin rash, or
  • itching.

Tell your doctor if you have serious side effects of Pradaxa including:

  • severe heartburn,
  • nausea, or
  • vomiting.

Dosage for Pradaxa

The usual recommended dose of Pradaxa is 150 mg taken orally, twice daily Pradaxa is administered in capsule form.

What Drugs, Substances, or Supplements Interact with Pradaxa?

Pradaxa may interact with antibiotics, St. John's wort, antifungal medications, aspirin or other NSAIDs, heart or blood pressure medication, HIV/AIDS medicine, or medicines used to prevent organ transplant rejection. Tell your doctor all medications and supplements you use.

Pradaxa During Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of Pradaxa in pregnant women. It is unknown if Pradaxa passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding. The safety and effectiveness of Pradaxa in pediatric patients has also not been established.

Additional Information

Our Pradaxa Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

Atrial fibrillation is a(n) ... See Answer
Pradaxa Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; pain or tight feeling in your chest, wheezing, difficult breathing; swelling of your face, lips, tongue, or throat.

Also seek emergency medical attention if you have symptoms of a spinal blood clot: back pain, numbness or muscle weakness in your lower body, or loss of bladder or bowel control.

Call your doctor at once if you have:

  • any bleeding that will not stop;
  • headache, weakness, dizziness, or feeling like you might pass out;
  • easy bruising or bleeding (nosebleeds, bleeding gums);
  • blood in your urine or stools, black or tarry stools;
  • cough with bloody mucus or vomit that looks like coffee grounds;
  • pink or brown urine;
  • joint pain or swelling; or
  • heavy menstrual bleeding.

Common side effects may include:

  • stomach pain or discomfort;
  • indigestion; or
  • nausea, diarrhea.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Pradaxa (Dabigatran Etexilate Mesylate)

SLIDESHOW

Heart Disease: Causes of a Heart Attack See Slideshow
Pradaxa Professional Information

SIDE EFFECTS

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Increased Risk of Thrombotic Events after Premature Discontinuation [see WARNINGS AND PRECAUTIONS ]
  • Risk of Bleeding [see WARNINGS AND PRECAUTIONS]
  • Spinal/Epidural Anesthesia or Puncture [see WARNINGS AND PRECAUTIONS ]
  • Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves [see WARNINGS AND PRECAUTIONS]
  • Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome [see WARNINGS AND PRECAUTIONS]

The most serious adverse reactions reported with PRADAXA were related to bleeding [see WARNINGS AND PRECAUTIONS].

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adult Trials

Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation

The RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) study provided safety information on the use of two doses of PRADAXA Capsules and warfarin [see Clinical Studies]. The numbers of patients and their exposures are described in Table 2. Limited information is presented on the 110 mg dosing arm because this dose is not approved.

Table 2 Summary of Treatment Exposure in RE-LY

PRADAXA Capsules 110 mg
twice daily
PRADAXA Capsules 150 mg
twice daily
Warfarin
Total number treated 5983 6059 5998
Exposure
  > 12 months 4936 4939 5193
  > 24 months 2387 2405 2470
Mean exposure (months) 20.5 20.3 21.3
Total patient-years 10,242 10,261 10,659

Drug Discontinuation in RE-LY

The rates of adverse reactions leading to treatment discontinuation were 21% for PRADAXA Capsules 150 mg and 16% for warfarin. The most frequent adverse reactions leading to discontinuation of PRADAXA Capsules were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).

Bleeding

[see WARNINGS AND PRECAUTIONS]

Table 3 shows the number of adjudicated major bleeding events during the treatment period in the RE-LY study, with the bleeding rate per 100 subject-years (%). Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of ≥2 g/dL, a transfusion of ≥2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome. Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.

Table 3 Adjudicated Major Bleeding Events in Treated Patientsa

Event PRADAXA Capsules
150 mg
N = 6059
n (%/yearb)
Warfarin
N = 5998
n (%/yearb)
PRADAXA Capsules
150 mg vs Warfarin
HR (95% CI)
Major Bleedingc 350 (3.47) 374 (3.58) 0.97 (0.84, 1.12)
  Intracranial Hemorrhage (ICH)d 23 (0.22) 82 (0.77) 0.29 (0.18, 0.46)
    Hemorrhagic Strokee 6 (0.06) 40 (0.37) 0.16 (0.07, 0.37)
    Other ICH 17 (0.17) 46 (0.43) 0.38 (0.22, 0.67)
  Gastrointestinal 162 (1.59) 111 (1.05) 1.51 (1.19, 1.92)
  Fatal Bleedingf 7 (0.07) 16 (0.15) 0.45 (0.19, 1.10)
    ICH 3 (0.03) 9 (0.08) 0.35 (0.09, 1.28)
    Non-intracranialg 4 (0.04) 7 (0.07) 0.59 (0.17, 2.02)
aPatients during treatment or within 2 days of stopping study treatment. Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories.
bAnnual event rate per 100 pt-years = 100 * number of subjects with event/subject-years. Subject-years is defined as cumulative number of days from first drug intake to event date, date of last drug intake + 2, death date (whatever occurred first) across all treated subjects divided by 365.25. In case of recurrent events of the same category, the first event was considered.
cDefined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of ≥2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome.
dIntracranial bleed included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.
eOn-treatment analysis based on the safety population, compared to ITT analysis presented in Section 14 Clinical Studies
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding
gNon-intracranial fatal bleed: Adjudicated major bleed as defined above and adjudicated death with primary cause from bleeding but without symptomatic intracranial bleed based on investigator's clinical assessment.

There was a higher rate of any gastrointestinal bleeds in patients receiving PRADAXA Capsules 150 mg than in patients receiving warfarin (6.6% vs 4.2%, respectively).

The risk of major bleeds was similar with PRADAXA Capsules 150 mg and warfarin across major subgroups defined by baseline characteristics (see Figure 1), with the exception of age, where there was a trend toward a higher incidence of major bleeding on PRADAXA Capsules (hazard ratio 1.2, 95% CI: 1.0 to 1.5) for patients ≥75 years of age.

Figure 1 Adjudicated Major Bleeding by Baseline Characteristics Including Hemorrhagic Stroke Treated Patients

Adjudicated Major Bleeding by Baseline Characteristics Including Hemorrhagic Stroke Treated Patients - Illustration

Note: The figure above presents effects in various subgroups all of which are baseline characteristics and all of which were pre-specified. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

Gastrointestinal Adverse Reactions

Patients on PRADAXA Capsules 150 mg had an increased incidence of gastrointestinal adverse reactions (35% vs 24% on warfarin). These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).

Hypersensitivity Reactions

In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA Capsules.

Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

PRADAXA Capsules was studied in 4387 patients in 4 pivotal, parallel, randomized, double-blind trials. Three of these trials were active-controlled (warfarin) (RE-COVER, RE-COVER II, and RE-MEDY), and one study (RE-SONATE) was placebo-controlled. The demographic characteristics were similar among the 4 pivotal studies and between the treatment groups within these studies. Approximately 60% of the treated patients were male, with a mean age of 55.1 years. The majority of the patients were white (87.7%), 10.3% were Asian, and 1.9% were black with a mean CrCl of 105.6 mL/min.

Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).

RE-COVER and RE-COVER II studies compared PRADAXA Capsules 150 mg twice daily and warfarin for the treatment of deep vein thrombosisand pulmonary embolism. Patients received 5-10 days of an approved parenteral anticoagulant therapy followed by 6 months, with mean exposure of 164 days, of oral only treatment; warfarin was overlapped with parenteral therapy. Table 4 shows the number of patients experiencing bleeding events in the pooled analysis of RE-COVER and RE-COVER II studies during the full treatment including parenteral and oral only treatment periods after randomization.

Table 4 Bleeding Events in RE-COVER and RE-COVER II Treated Patients

Bleeding Events—Full Treatment Period Including Parenteral
Treatment
PRADAXA
Capsules
150 mg twice daily
N (%)
Warfarin
N (%)
Hazard Ratio
(95% CI)c
Patients N=2553 N=2553
Major bleeding eventa 37 (1.4) 51 (2.0) 0.73
(0.48, 1.11)
  Fatal bleeding 1 (0.04) 2 (0.1)
  Bleeding in a critical area or organ 7 (0.3) 15 (0.6)
  Fall in hemoglobin ≥2 g/dL or transfusion≥2 units of whole blood or packed red blood cells 32 (1.3) 38 (1.5)
Bleeding sites for MBEb
  Intracranial 2 (0.1) 5 (0.2)
  Retroperitoneal 2 (0.1) 1 (0.04)
  Intraarticular 2 (0.1) 4 (0.2)
  Intramuscular 2 (0.1) 6 (0.2)
  Gastrointestinal 15 (0.6) 14 (0.5)
  Urogenital 7 (0.3) 14 (0.5)
  Other 8 (0.3) 8 (0.3)
Clinically relevant non-major bleeding 101 (4.0) 170 (6.7) 0.58
(0.46, 0.75)
Any bleeding 411 (16.1) 567 (22.7) 0.70
(0.61, 0.79)
Note: MBE can belong to more than one criterion.
aPatients with at least one MBE
bBleeding site based on investigator assessment. Patients can have more than one site of bleeding.
cConfidence interval

The rate of any gastrointestinal bleeds in patients receiving PRADAXA Capsules 150 mg in the full treatment period was 3.1% (2.4% on warfarin).

The RE-MEDY and RE-SONATE studies provided safety information on the use of PRADAXA Capsules for the reduction in the risk of recurrence of deep vein thrombosis and pulmonary embolism.

RE-MEDY was an active-controlled study (warfarin) in which 1430 patients received PRADAXA Capsules 150 mg twice daily following 3 to 12 months of oral anticoagulant regimen. Patients in the treatment studies who rolled over into the RE-MEDY study had a combined treatment duration of up to more than 3 years, with mean exposure of 473 days. Table 5 shows the number of patients experiencing bleeding events in the study.

Table 5 Bleeding Events in RE-MEDY Treated Patients

PRADAXA
Capsules
150 mg twice daily
N (%)
Warfarin
N (%)
Hazard Ratio
(95% CI)c
Patients N=1430 N=1426
Major bleeding eventa 13 (0.9) 25 (1.8) 0.54
(0.25, 1.16)
  Fatal bleeding 0 1 (0.1)
  Bleeding in a critical area or organ 7 (0.5) 11 (0.8)
  Fall in hemoglobin ≥2 g/dL or transfusion ≥2 units of whole blood or packed red blood cells 7 (0.5) 16 (1.1)
Bleeding sites for MBEb
  Intracranial 2 (0.1) 4 (0.3)
  Intraocular 4 (0.3) 2 (0.1)
  Retroperitoneal 0 1 (0.1)
  Intraarticular 0 2 (0.1)
  Intramuscular 0 4 (0.3)
  Gastrointestinal 4 (0.3) 8 (0.6)
  Urogenital 1 (0.1) 1 (0.1)
  Other 2 (0.1) 4 (0.3)
Clinically relevant non-major bleeding 71 (5.0) 125 (8.8) 0.56
(0.42, 0.75)
Any bleeding 278 (19.4) 373 (26.2) 0.71
(0.61, 0.83)
Note: MBE can belong to more than one criterion.
aPatients with at least one MBE.
bBleeding site based on investigator assessment. Patients can have more than one site of bleeding.
cConfidence interval

In the RE-MEDY study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA Capsules 150 mg was 3.1% (2.2% on warfarin).

RE-SONATE was a placebo-controlled study in which 684 patients received PRADAXA Capsules 150 mg twice daily following 6 to 18 months of oral anticoagulant regimen. Patients in the treatment studies who rolled over into the RE-SONATE study had combined treatment duration up to 9 months, with mean exposure of 165 days. Table 6 shows the number of patients experiencing bleeding events in the study.

Table 6 Bleeding Events in RE-SONATE Treated Patients

PRADAXA
Capsules
150 mg twice daily
N (%)
Placebo
N (%)
Hazard Ratio
(95% CI)c
Patients N=684 N=659
Major bleeding eventa 2 (0.3) 0
  Bleeding in a critical area or organ 0 0
  Gastrointestinalb 2 (0.3) 0
Clinically relevant non-major bleeding 34 (5.0) 13 (2.0) 2.54
(1.34, 4.82)
Any bleeding 72 (10.5) 40 (6.1) 1.77
(1.20, 2.61)
Note: MBE can belong to more than one criterion.
aPatients with at least one MBE.
bBleeding site based on investigator assessment. Patients can have more than one site of bleeding.
cConfidence interval

In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA Capsules 150 mg was 0.7% (0.3% on placebo).

Clinical Myocardial Infarction Events

In the active-controlled VTE studies, a higher rate of clinical myocardial infarction was reported in patients who received PRADAXA Capsules [20 (0.66 per 100 patient-years)] than in those who received warfarin [5 (0.17 per 100 patient-years)]. In the placebo-controlled study, a similar rate of nonfatal and fatal clinical myocardial infarction was reported in patients who received PRADAXA Capsules [1 (0.32 per 100 patient-years)] and in those who received placebo [1 (0.34 per 100 patient-years)].

Gastrointestinal Adverse Reactions

In the four pivotal studies, patients on PRADAXA Capsules 150 mg had a similar incidence of gastrointestinal adverse reactions (24.7% vs 22.7% on warfarin). Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA Capsules 7.5% vs 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs 1.7%, respectively.

Hypersensitivity Reactions

In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA Capsules.

Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery

PRADAXA Capsules was studied in 5476 patients, randomized and treated in two double-blind, active-controlled non-inferiority trials (RENOVATE and RE-NOVATE II). The demographic characteristics were similar across the two studies and between the treatment groups within these studies. Approximately 45.3% of the treated patients were male, with a mean age of 63.2 years. The majority of the patients were white (96.1%), 3.6% were Asian, and 0.3% were black with a mean CrCl of 92 mL/min.

Bleeding events for the RE-NOVATE and RE-NOVATE II studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or retroperitoneal bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells, requiring treatment cessation or leading to re-operation.

The RE-NOVATE study compared PRADAXA Capsules 75 mg taken orally 1-4 hours after surgery followed by 150 mg once daily, PRADAXA Capsules 110 mg taken orally 1-4 hours after surgery followed by 220 mg once daily and subcutaneous enoxaparin 40 mg once daily initiated the evening before surgery for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who had undergone hip replacement surgery. The RE-NOVATE II study compared PRADAXA Capsules 110 mg taken orally 1-4 hours after surgery followed by 220 mg once daily and subcutaneous enoxaparin 40 mg once daily initiated the evening before surgery for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who had undergone hip replacement surgery. In the RE-NOVATE and RE-NOVATE II studies, patients received 28-35 days of PRADAXA Capsules or enoxaparin with median exposure of 33 days. Tables 7 and 8 show the number of patients experiencing bleeding events in the analysis of RE-NOVATE and RE-NOVATE II.

Table 7 Bleeding Events in RE-NOVATE Treated Patients

PRADAXA Capsules 220 mg
N (%)
Enoxaparin
N (%)
Patients N=1146 N=1154
Major bleeding event 23 (2.0) 18 (1.6)
Clinically relevant non-major bleeding 48 (4.2) 40 (3.5)
Any bleeding 141 (12.3) 132 (11.4)

Table 8 Bleeding Events in RE-NOVATE II Treated Patients

PRADAXA Capsules 220 mg
N (%)
Enoxaparin
N (%)
Patients N=1010 N=1003
Major bleeding event 14 (1.4) 9 (0.9)
Clinically relevant non-major bleeding 26 (2.6) 20 (2.0)
Any bleeding 98 (9.7) 83 (8.3)

In the two studies, the rate of major gastrointestinal bleeds in patients receiving PRADAXA Capsules and enoxaparin was the same (0.1%) and for any gastrointestinal bleeds was 1.4% for PRADAXA Capsules 220 mg and 0.9% for enoxaparin.

Gastrointestinal Adverse Reactions

In the two studies, the incidence of gastrointestinal adverse reactions for patients on PRADAXA Capsules 220 mg and enoxaparin was 39.5% and 39.5%, respectively. Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA Capsules 220 mg in 4.1% vs. 3.8% on enoxaparin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 0.6% vs 1.0%, respectively.

Hypersensitivity Reactions

In the two studies, drug hypersensitivity (such as urticaria, rash, and pruritus) was reported in 0.3% of patients receiving PRADAXA Capsules 220 mg.

Clinical Myocardial Infarction Events

In the two studies, clinical myocardial infarction was reported in 2 (0.1%) of patients who received PRADAXA Capsules 220 mg and 6 (0.3%) of patients who received enoxaparin.

Pediatric Trials

Treatment of VTE in Pediatric Patients

The safety of PRADAXA in the treatment of VTE in pediatric patients was studied in one phase III trial (DIVERSITY). The DIVERSITY study was a randomized, open-label, active-controlled, parallel-group trial comparing PRADAXA with standard of care – SOC (vitamin K antagonists, low molecular weight heparin, or fondaparinux). There were 266 pediatric patients who received study treatment, 176 patients treated with PRADAXA and 90 patients treated with SOC. Patients on PRADAXA received age- and weight-adjusted doses of an age-appropriate formulation of PRADAXA (capsules, pellets, or oral solution) twice daily.

Patients had a median age of 14 years (range: 0-17 years), 92% were white, and half the patients were male (50%). Following at least 5 days of parenteral anticoagulant therapy, the median duration of treatment with PRADAXA was 85 days (range: 1-105). Patients with estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73m2 were excluded from the trial.

Bleeding

Data on adjudicated major bleeding, clinically relevant non-major (CRNM) bleeding and minor bleeding events, for the PRADAXA group and the SOC group in the DIVERSITY study, are reported in Table 9. There was no statistically significant difference in the time to first major bleeding event.

Table 9 Summary of All Adjudicated Bleeding Events During On-Treatment Period in DIVERSITY

PRADAXA
N (%)
Standard of Care (SOC)
N (%)
Patients N=176 N=90
Major bleeding event1 4 (2.3) 2 (2.2)
  Fatal bleeding 0 1 (1.1)
Clinically relevant non-major bleeding 2 (1.1) 1 (1.1)
Minor bleeding 33 (19) 21 (23)
Major and clinically relevant non-major bleeding 6 (3.4) 3 (3.3)
Any bleeding 38 (22) 22 (24)
1Major bleeding event if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.

Site-specific bleeding rates were comparable between the two arms, with the exception of the rate of any gastrointestinal bleeds (5.7% in PRADAXA arm vs 1.8% in SOC arm).

Gastrointestinal Adverse Reactions

The incidence of gastrointestinal adverse reactions for patients on PRADAXA and SOC was 32% and 12%, respectively, with the following occurring in ≥5% of patients taking PRADAXA: dyspepsia (including term gastro-esophageal reflux disease, gastric pH decreased and esophagitis) in 9% (vs 2%), upper abdominal pain in 5% (vs 1%), vomiting in 8% (vs 2%), nausea 5% (vs 4%), and diarrhea 5% (vs 1%).

Reduction in Risk of Recurrence of VTE in Pediatric Patients

The safety of PRADAXA in the reduction in the risk of recurrence of VTE in pediatric patients was studied in one open-label single-arm trial (Study 2). Study 2 enrolled patients who required further anticoagulation due to the presence of a clinical risk factor after completing the initial treatment for confirmed VTE (for at least 3 months) or after completing the DIVERSITY study and received PRADAXA until the clinical risk factor resolved, or up to a maximum of 12 months. There were 213 pediatric patients treated with PRADAXA, in a similar fashion as in the DIVERSITY trial.

Patients had a median age of 14 years (range: 0-18 years), 91% were white, and 55% of patients were male. Patients previously enrolled on DIVERSITY accounted for 43% of patients enrolled on Study 2 (29% from PRADAXA arm and 14% from SOC arm). The median duration of treatment with PRADAXA in Study 2 was 42 weeks (range: 0-56 weeks), with 45% of patients completing the 12-month planned duration, 17% stopping due to resolution of VTE risk factors, 12% stopping due to failure to attain target dabigatran concentration and 6% had an adverse event leading to discontinuation.

During the on-treatment period of Study 2, 3 patients (1.4%) had a major bleeding event, 3 patients (1.4%) had a clinically relevant non-major bleeding event, and 44 patients (20%) had a minor bleeding event. The most common drug-related adverse reactions were dyspepsia (5%), epistaxis (3.3%), nausea (3.3%) and menorrhagia (2.8%).

The adverse reaction profile in pediatric patients was generally consistent with that of adult patients.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of PRADAXA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post approval use of PRADAXA: angioedema, thrombocytopenia, esophageal ulcer, alopecia, neutropenia, agranulocytosis.

DRUG INTERACTIONS

Reduction Of Risk Of Stroke And Systemic Embolism In Non-Valvular Atrial Fibrillation In Adult Patients

The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided [see CLINICAL PHARMACOLOGY].

P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran [see CLINICAL PHARMACOLOGY]. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone.

In patients with moderate renal impairment (CrCl 30-50 mL/min), reduce the dose of PRADAXA to 75 mg twice daily when administered concomitantly with the P-gp inhibitors dronedarone or systemic ketoconazole. The use of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin, and ticagrelor does not require a dose adjustment of PRADAXA. These results should not be extrapolated to other P-gp inhibitors [see WARNINGS AND PRECAUTIONS, Use In Specific Populations, and CLINICAL PHARMACOLOGY].

The concomitant use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) should be avoided [see WARNINGS AND PRECAUTIONS, Use In Specific Populations, and CLINICAL PHARMACOLOGY].

Treatment And Reduction In The Risk Of Recurrence Of Deep Venous Thrombosis And Pulmonary Embolism In Adult Patients

Avoid use of PRADAXA and P-gp inhibitors in patients with CrCl <50 mL/min [see WARNINGS AND PRECAUTIONS, Use In Specific Populations, and CLINICAL PHARMACOLOGY].

Prophylaxis Of Deep Vein Thrombosis And Pulmonary Embolism In Adult Patients Following Hip Replacement Surgery

In patients with CrCl ≥50 mL/min who have concomitant administration of P-gp inhibitors such as dronedarone or systemic ketoconazole, it may be helpful to separate the timing of administration of PRADAXA and the P-gp inhibitor by several hours. The concomitant use of PRADAXA and P-gp inhibitors in patients with CrCl <50 mL/min should be avoided [see WARNINGS AND PRECAUTIONS, Use In Specific Populations and CLINICAL PHARMACOLOGY].

Treatment And Reduction In Risk Of Recurrence Of VTE In Pediatric Patients

The concomitant use of PRADAXA with P-gp inhibitors has not been studied in pediatric patients but may increase exposure to dabigatran [see WARNINGS AND PRECAUTIONS].

Read the entire FDA prescribing information for Pradaxa (Dabigatran Etexilate Mesylate)

© Pradaxa Patient Information is supplied by Cerner Multum, Inc. and Pradaxa Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors